Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Apr;266(4):888-901.
doi: 10.1007/s00415-019-09211-5. Epub 2019 Feb 7.

Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France

Christine Lebrun-Frenay  1 , Antoine Moulignier  2 , Charles Pierrot-Deseilligny  3 , Rabah Benrabah  4 , Thibault Moreau  5 , Catherine Lubetzki  6 , Françoise Monchecourt  7 ; Copaxone Observatory
Collaborators, Affiliations
Observational Study

Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France

Christine Lebrun-Frenay et al. J Neurol. 2019 Apr.

Abstract

The benefits provided by disease-modifying treatments in multiple sclerosis have been demonstrated in clinical trials, but the extent to which they can be extrapolated to everyday care is less clear, as are the long-term benefits of treatment. The objective of this prospective observational cohort study performed in France was to evaluate the effectiveness and safety of glatiramer acetate in patients with relapsing-remitting multiple sclerosis over a 5-year period. All neurologists in France were invited to participate and enroll adult patients starting a first treatment with brand glatiramer acetate 20 mg. Given the observational nature of the study, no fixed study visits were imposed; consultations took place according to the investigator's normal practice. Occurrence of disease exacerbations and adverse events was documented and neurological disability evaluated with the EDSS at each consultation. Overall, 852 patients were analysable and 269 took glatiramer acetate continuously for 5 years. Median treatment duration was 3.4 years. Principal reasons for discontinuation were inadequate efficacy (38.9%), local tolerability (22.6%) and personal convenience (21.3%). Age, employment status, baseline EDSS score and number of previous exacerbations were variables associated with treatment persistence. The annualised exacerbation rate (5 years) was 0.41 [95% CI 0.39-0.44]; 316 patients (37.2%) remained exacerbation-free throughout. The risk of confirmed disability worsening (5 years) was 43.8% [95% CI 39.9-47.9%]. The most frequent adverse drug reactions were local injection site reactions (584 patients; 68.5%) and systemic immediate post-injection reactions (168 patients; 19.7%). Overall, these findings are consistent with those of previous clinical trials.

Keywords: Disease-modifying treatment; France; Glatiramer acetate; Observational study; Relapsing–remitting multiple sclerosis.

PubMed Disclaimer

Conflict of interest statement

CLF has received consultancy or speakers fees from Biogen Idec, Merck Serono, Genzyme, Almirall, Allergan, Teva, Sanofi, Bayer Schering. AM, CPD and RB have received consultancy fees from Sanofi and Teva. TM and CL has received consultancy fees or speaking fees from Biogen Idec, Sanofi, Genzyme, Teva,Pharma, Bayer Schering, Merck Serono, Roche, Almirall and Novartis. FM is employee of Teva Pharma.

Figures

Fig. 1
Fig. 1
Patient distribution. GA glatiramer acetate, FU follow-up
Fig. 2
Fig. 2
Probability of persistence with AG treatment over the 5-year study period. Data are presented as a Kaplan–Meier survival curve
Fig. 3
Fig. 3
Patient variables independently associated with treatment persistence (a; N = 715) and with clinical response (b; N = 661) in patients treated with glatiramer acetate. Data are presented as hazard ratios or odds ratios with their 95% confidence intervals
Fig. 4
Fig. 4
Annualised exacerbation rate over the course of the study
Fig. 5
Fig. 5
Time to confirmed worsening of disability: Kaplan–Meier survival analysis
Fig. 6
Fig. 6
Non-serious adverse drug reactions documented during the study
See this image and copyright information in PMC

References

    1. Foulon S, Weill A, Maura G, Dalichampt M, Debouverie M, Moreau T. Prévalence de la sclérose en plaques en France en 2012 et mortalité associée en 2013 à partir des données du Sniiram-PMSI. Rev Epidemiol Santé Publique. 2015;63:S14–S22.
    1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–1259. doi: 10.1016/S0140-6736(17)32154-2. - DOI - PMC - PubMed
    1. Palace J, Duddy M, Bregenzer T, Lawton M, Zhu F, Boggild M, Piske B, Robertson NP, Oger J, Tremlett H, Tilling K, Ben-Shlomo Y, Dobson C. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6years: a clinical cohort study with natural history comparator. Lancet Neurol. 2015;14:497–505. doi: 10.1016/S1474-4422(15)00018-6. - DOI - PubMed
    1. Zhornitsky S, Greenfield J, Koch MW, Patten SB, Harris C, Wall W, Alikhani K, Burton J, Busche K, Costello F, Davenport JW, Jarvis SE, Lavarato D, Parpal H, Patry DG, Yeung M, Metz LM. Long-term persistence with injectable therapy in relapsingremitting multiple sclerosis: an 18-year observational cohort study. PLoS One. 2015;10:e0123824. doi: 10.1371/journal.pone.0123824. - DOI - PMC - PubMed
    1. Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology. 2009;73:1616–1623. doi: 10.1212/WNL.0b013e3181c1e44f. - DOI - PMC - PubMed

Publication types

Substances